Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

INTRODUCTION: Immunotherapy with checkpoint inhibitors (CPIs) has revolutionised cancer treatment but has no convincing effect in metastatic castration-resistant prostate cancer (mCRPC). It has been suggested that a combination of CPI and hypofractionated stereotactic body radiotherapy (SBRT) may wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spindler, Nicklas Juel, Persson, Gitte Fredberg, Theile, Susann, Nielsen, Dorte Lisbeth, Høgdall, Estrid V, Al-Farra, Gina, Hendel, Helle Westergren, Lorentzen, Torben, Svane, Inge Marie, Lindberg, Henriette, Eefsen, Rikke Løvendahl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887717/
https://www.ncbi.nlm.nih.gov/pubmed/36717150
http://dx.doi.org/10.1136/bmjopen-2022-063500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887717/
https://www.ncbi.nlm.nih.gov/pubmed/36717150
http://dx.doi.org/10.1136/bmjopen-2022-063500

Ejemplares similares